Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
Key facts
- Who runs it
- Abramson Cancer Center at Penn Medicine
- Where
- Philadelphia, United StatesSee the site
- Trial code
- Status
- Terminated
- Phase
- Phase 1
- People taking part
- 1 person enrolled
- Started
- 26 Aug 2020
- Ended
- 31 Jan 2024
- Type of study
- Interventional
- Treatments tested
- Nivolumab
- Ipilimumab
- bland embolization
- Record updated
- 26 April 2024
- Why it stopped
- failure to accrue
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Metastatic renal cell carcinoma with unresected primary tumor or with metastasis amenable to embolization
- No prior immune checkpoint therapy
- Primary tumor or metastasis amenable to percutaneous embolization per review by the treating interventional oncologist; Patent feeding artery to tumor > 2 mm diameter without macroscopic arteriovenous fistula/shunt
- Additional metastatic site > 1 cm assessable for response by RECIST 1.1
- Adequate organ function by screening laboratory studies within 30 days of embolization; platelets > 50K, correctable by transfusion; INR < 1.5, correctable by transfusion; creatinine < 2.0
- ECOG performance status 0-2
- Age ≥ 18 years
- Have signed the current approved informed consent form and be willing and able to comply with this protocol
- Women of childbearing potential (WOCBP) must use appropriate method(s) of contraception. WOCBP should use an adequate method to avoid pregnancy for 5 months after the last dose of study drug
- Women of childbearing potential must have a negative serum or urine pregnancy test
- Men who are sexually active with WOCBP must use any contraceptive method with a failure rate of less than 1% per year Men receiving nivolumab and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 7 months after the last dose
Who cannot take part
- Glucocorticoid (> 10 mg daily prednisone equivalents) or immunosuppressant therapy
- Autoimmune disorder; subjects are permitted to enroll if they have vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone replacement, psoriasis not requiring systemic treatment
- Immunodeficiency syndrome
- Active infection requiring systemic therapy
- Any other medical or personal condition that, in the opinion of the site investigator, may potentially compromise the safety or compliance of the patient, or may preclude the patient's successful completion of the clinical trial
- Positive test for hepatitis B virus surface antigen (HBV sAg) or hepatitis C virus ribonucleic acid (HCV antibody) indicating acute or chronic infection
- Contrast allergy not mitigated by usual prophylaxis
- Untreated CNS metastasis
Where in United States
- Hospital of the University of PennsylvaniaPhiladelphia, United States
About the trial
What the trial wants to find out
This single center phase 1 trial will study the combination of nivolumab+ipilimumab with embolization in participants with renal cell carcinoma. The study will evaluate the safety of embolotherapy in patients with metastatic RCC receiving nivolumab+ipilimumab. The hypothesis is that the number of serious adverse events will be no greater than the number of serious adverse events for both therapies combined.
The group in the trial
- Ipilimumab +Nivolumab with EmbolizationTreatment being tested
Patients initiate ICI therapy with Nivolumab 3 mg/kg + ipilimumab 1/mg/kg IV every 3 weeks x 4 cycles, followed by nivolumab 480mg flat dose IV every four weeks for a total of 6 months of therapy unless stopped for confirmed progression or intolerable toxicities. Patients will receive 2 cycles of systemic therapy followed by embolization of their primary tumor or metastatic lesion(s) and continue systemic therapy subsequently.
Treatment: Nivolumab, Ipilimumab, and bland embolization
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- UPCC06820 Phase 1 Trial of Nivolumab + Ipilimumab With Immunostimulatory Embolization for Stage 4 Renal Cell Carcinoma With Unresected Primary
- Record updated
- 26 April 2024